Sugi Predict

Sugi Predict / Compounds / SCHEMBL30029172

SCHEMBL30029172

SCHEMBL30029172

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 9/20 0.59
▸ VIPR2 P41587 5/20 0.54
▸ VIPR1 P32241 4/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.53
▸ PTH1R Q03431 2/20 0.52
▸ CTSD P07339 1/20 0.52
▸ BACE2 Q9Y5Z0 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30029357 0.94 BACE1 (0.53) BACE1VIPR2VIPR1RXFP1PTH1R
SCHEMBL29397489 0.92 BACE1 (0.62) BACE1CTSDBACE2
SCHEMBL30028783 0.91 RXFP1 (0.67) RXFP1PTH1R
SCHEMBL29416133 0.90 BACE1 (0.58) BACE1VIPR2VIPR1RXFP1PTH1R
SCHEMBL29867509 0.90 VIPR2 (0.64) BACE1VIPR2VIPR1PTH1R
SCHEMBL31182908 0.89 VIPR1 (0.65) BACE1VIPR2VIPR1PTH1RBACE2
SCHEMBL29686720 0.89 BACE1 (0.69) BACE1VIPR2VIPR1RXFP1PTH1R
SCHEMBL29396146 0.89 BACE1 (0.62) BACE1CTSDBACE2
SCHEMBL30168781 0.88 TFPI (0.63) VIPR2VIPR1RXFP1PTH1R
SCHEMBL30431840 0.88 BACE1 (0.66) BACE1VIPR2VIPR1RXFP1PTH1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383605-B2 Exenatide analog and use thereof ANYGEN CO., LTD. (KR) 2025-08-12 — — US disclosed
CN-115380043-A Exenatide analogue and application thereof 安医健有限公司 2022-11-22 — — CN disclosed
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF ANYGEN CO., LTD., (KR) 2022-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12383605-B2 Exenatide analog and use thereof GLP1R, IAPP, GIPR BACE1 822/4885VIPR2 95/4885VIPR1 76/4885
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF GLP1R, IAPP, GIPR BACE1 822/4885VIPR2 95/4885VIPR1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback